Crown Laboratories, Inc., a privately held player in the skincare industry, agreed on Monday to acquire Revance Therapeutics, Inc. (NASDAQ:RVNC). Under the terms of the agreement, Crown will commence ...

Revance, a fast-growing global leader in aesthetics and skincare, today announced its participation in the 2026 International Master Course on Aging Science (IMCAS) World Congress, which will be held ...

Revance Therapeutics' share price has been characterised by volatility ever since its IPO - but today shares trade close to an all-time low. The company's focus is on maximising the potential of ...

AbbVie’s Botox is a major blockbuster and king of the anti-wrinkle aesthetics market, but there are new contenders coming for its crown. Revance, which markets its rival anti-wrinkle therapy Daxxify, ...

RHA® Dynamic Volume delivers high patient satisfaction with youthful, attractive cheeks at rest and in motion.1 RHA® Dynamic Volume provides deep structural support while allowing for natural tissue ...

Increased offer price to $3.65 per share, a $0.55 per share increase Improved offer unanimously approved by Revance Board of Directors Crown to extend tender offer until 11:59 p.m., Eastern Time, on ...

Revance Therapeutics, Inc. operates in the aesthetics and therapeutics markets, selling Daxxify and RHA Collection of dermal fillers in the U.S. Despite positive guidance for 2024, the Revance stock ...

(Reuters) -Crown Laboratories would buy the anti-wrinkle injection maker Revance Therapeutics at a roughly 50% lower price compared to an original agreement signed in August, the companies said on ...

(Reuters) - The U.S. health regulator has approved expanding the use of Revance Therapeutics' Daxxify to treat a painful neck muscle condition, intensifying the anti-wrinkle injection's rivalry with ...

Find out why Revance Therapeutics Daxxify made this year's list ...

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (RVNC), today announced that the company will release first quarter 2023 financial results on Tuesday, May 9, 2023, after the close of ...

Jan 4 (Reuters) - A federal judge on Wednesday said Botox maker AbbVie's ABBV.N Allergan unit can move ahead with its lawsuit accusing Revance Therapeutics RVNC.O of taking its confidential data to ...